Belantamab mafodotin for Multiple Myeloma
by Dr. C.H. Weaver M.D. 6/2020
Belantamab mafodotin produced sustained clinically meaningful responses in patients with relapsed or refractory multiple myeloma, according to findings from the DREAMM-2 clinical trial presented at the American Society of Clinical Oncology Annual Meeting in May 2020.
About Belantamab mafodotin
Belantamab mafodotin is a monoclonal antibody-drug conjugate, a type of precision cancer medicine that directly targets a B-cell maturation antigen (BCMA) a protein on the surface on myeloma cells.
At the 2020 meeting researchers presented an update on heavily pretreated, relapsed or refractory multiple myeloma patients treated with single-agent Belantamab mafodotin. The overall response rate was 31% in the 2.5 mg/kg group and 35% in the 3.4 mg/kg group of patients and the very good partial response rates were 19% and 24%. They estimated that the 1-year overall survival rate was 53%, and the median remission duration was about 11 months.
Treatment was generally well tolerated with the most common side effects being low blood counts however the researchers did report keratopathy – a type of corneal inflammation in the eye also occurred but did not go into detail regarding this potentially significant side effect.
Research of Belantamab mafodotin is ongoing in combination with other anti-myeloma medications and the company in expected to seek US FDA approval later this year.